STTR Phase I: Advanced Microfluidic Devices for Point-of-Care COVID-19 Serological Testing

STTR 第一阶段：用于护理点 COVID-19 血清学检测的先进微流体设备

• 批准号: 2032222
• 负责人: Thomas Reilly
• 金额: $ 25.6万
• 依托单位: Access Sensor Technologies
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-15 至 2022-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2032222&HistoricalAwards=false
• 关键词: STTR; Phase; Advanced; Microfluidic; Devices

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project may reach millions of people and provide a key tool in safeguarding the public health through the COVID-19 pandemic. Sensitive, selective and quantitative detection usually requires complex laboratory-based methods and instrumentation to achieve consistent results; however, this project advances technologies to simplify the process. Antibody testing provides information regarding previous infections; a simple tool to detect presence at low concentrations enables better testing to manage social distancing needs. The proposed technology aims to make blood testing for SARS-Cov-2 simple and quantitative for two types of antibodies. The device will be developed to take patient samples directly with no complicated sample prep. Unique reagents will be created for selective detection of the SARS-CoV-2 antibodies. This Small Business Technology Transfer (STTR) Phase I project aims to develop the next generation of low-cost point of care immunoassay technology with direct application to infectious disease detection. The technology proposed here combines a new approach to controlling capillary flow driven systems applied to the steps of a traditional ELISA in a disposable device. The device developed in this project will detect SARSCoV-2 specific antibodies in patient samples, and will be able to provide information about the phase of the immune response of a patient. Additionally, adaption of ELISA-like enzymatic amplification into a point-of-care device will provide greater sensitivity and selectivity than traditional lateral flow assays, increasing assay sensitivity and improving detection of early infections. The immunoassays will be evaluated with deidentified patient samples and compared to state of the art laboratory-based detection methods.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小型企业技术转移（STTR）I阶段项目的更广泛的影响/商业潜力可能吸引数百万人，并提供了通过COVID-19-19的大流行保护公共卫生的关键工具。敏感，选择性和定量检测通常需要复杂的基于实验室的方法和仪器才能获得一致的结果；但是，该项目推动了简化过程的技术。抗体测试提供有关先前感染的信息；一个以低浓度检测存在的简单工具，可以更好地测试社会疏远的需求。拟议的技术旨在对SARS-COV-2进行血液测试简单且定量，以实现两种类型的抗体。将开发该设备以直接采集患者样品，而没有复杂的样品准备。将创建独特的试剂，以选择性检测SARS-COV-2抗体。这个小型企业技术转移（STTR）I期项目旨在开发下一代的低成本护理点免疫测定技术，并直接应用于传染病检测。 这里提出的技术结合了一种新的方法来控制毛细管流动驱动的系统，该系统应用于一次性设备中传统ELISA的步骤。该项目开发的设备将检测患者样品中的SARSCOV-2特定抗体，并能够提供有关患者免疫反应阶段的信息。此外，与传统的侧向流量测定法相比，ELISA样酶扩增的适应性将提供更高的灵敏度和选择性，从而提高测定敏感性并改善对早期感染的检测。免疫测定将通过具有死亡的患者样本进行评估，并与最先进的基于实验室的检测方法进行比较。该奖项反映了NSF的法定任务，并使用基金会的智力优点和更广泛的影响评估审查标准，认为值得通过评估来获得支持。